Prospects for cytokine and chemokine biotherapy

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2682-2686

  Oppenheim, Joost J ^a   Murphy, William J ^b   Chertov, Oleg ^b   Schirrmacher, Volker ^c   Wang, Ji Ming ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL LINE; CHEMOTAXIS; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; MICE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031426424     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Hersh, E. M., and Oppenheim, J. J. Impaired in vitro lymphocyte transformation in Hodgkin's disease. N. Engl. J. Med., 273: 1006-1012, 1965.
2. Yamamoto, N., Zou, J-P., Li, X-F., Takenaka, H., Noda, S., Fujii, T., Ono, S., Kobayashi, Y., Mukaida, N., Matsushima, K., Fujiwara, H., and Hamaoka, T. Regulatory mechanisms for production of IFN-γ and TNF by anti-tumor T cells or macrophages in the tumor-bearing state. J. Immunol., 154: 2281-2290, 1995.
3. Janik, J. E., and Steis, R. G. Interferon therapy for malignant and nonmalignant disease. In: J. J. Oppenheim, J. L. Rossio, and A. J. H. Gearing (eds.), Clinical Applications of Cytokines, pp. 135-146. New York: Oxford University Press Inc., 1993.
4. Creekmore, S. P., Reynolds, C. W., Hecht, T. T., Urba, W. J., and Longo, D. L. Interleukin 2 therapy for human cancer. In: J. J. Oppenheim, J. L. Rossio, and A. J. H. Gearing (eds.), Clinical Applications of Cytokines, pp. 147-154, New York: Oxford University Press, Inc., 1993.
5. Lin, W. C., Yasumura, S., Suminami, Y., Sung, M. W., Nagashima, S., Stanson, J., and Whiteside, T. L. Constitutive production of interleukin 2 by human carcinoma cells, expression of receptors for IL-2 and tumor cell growth. J. Immunol., 155: 4805-4816, 1995.
6. Neta, R., and Oppenheim, J. J. IL-1: Can we exploit Jekyll and subjugate Hyde? In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer Updates, Vol. 2, pp. 1-12. New York: J. B. Lippincott Co., 1992.
7. Onozaki, K., Matsushima, K., Aggarwal, B. B., and Oppenheim, J. J. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J. Immunol., 135: 3962-3968, 1985.
8. Douvdevani, A., Huleihelm, A., Zoller, M., Segal, S., and Apte, R. N. Reduced tumorigenicity of fibrosarcoma which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer. Int. J. Cancer, 51: 822-830, 1992.
9. Bani, M. R., Garofalo, A., Scanziani, E., and Giavazzi, R. Effects of IL-1β on metastasis formation in different tumor systems. J. Natl. Cancer Inst., 83: 119-123, 1991.
10. Kopp, W. C., Urba, W. J., Rager, H. C., Alvord, W. G., Oppenheim, J. J., Smith, J. W., II, and Longo, D. L. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin. Cancer Res., 2: 501-506, 1996.
11. Neta, R., Douches, S., and Oppenheim, J. Interleukin 1 is a radioprotector. J. Immunol., 136: 2483-2488, 1987.
12. Smith, J. W., II, Urba, W. J. Curti, B. D., Elwood, L. J., Steis, R. G., Janik, J. E., Sharfman, W. H., Miller, L. L., Fenton, R. G., Colon, K. C., Sznol, M., Creekmore, S. P., Wells, N. F., Ruscetti, F. W., Keller, J. R., Hestdal, K., Shimizu, M., Rossio, J., Alvord, W. G., Oppenheim, J. J., and Longo, D. L. The toxic and hematologic effects of interleukin-1α administered in a Phase I trial to patients with advanced malignancies. J. Clin. Oncol., 10: 1141-1152, 1992.
13. Smith, J. W., II, Longo, D. L., Alvord, W. G., Janik, J. E., Sharfman, W. H., Gause, B., Curti, B., Creekmore, S., Holmlund, J., Fenton, R. G., Sznol, M., Miller, L., Shimizu, M., Oppenheim, J. J., Feim, S., Hursey, J., Powers, G., and Urba, W. J. The effects of interleukin-1α treatment on platelet recovery after high-dose carboplatin. N. Engl. J. Med., 328: 756-761, 1993.
14. Quesada, J. R., Reuben, J., Manning, J. T., Hersh, E. M., and Gutterman, J. U. α-Interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med., 310: 15-18, 1984.
15. Talpaz, M., Kantarjian, H., Kurzock, R., Trajillo, J. M., and Gutterman, J. U. Interferon-α produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Intern. Med., 114: 532-538, 1991.
16. Mu, J., Zou, J-P, Yamamoto, N., Tsutsui, T., Tai, X. G., Kobayashi, M., Herrmann, S., Fujiwara, H., and Hamaoka, T. Administration of IL-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55: 4404-4408, 1995.
17. Dranoff, G., Gaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
18. Oppenheim, J. J., Wang, J. M., Chertov, O., Taub, D. D., and Ben-Baruch, A. Chemokines in transplantation. In: N. L. Tilney, T. B. Storm, and L. C. Paul (eds.), Transplantation Biology: Cellular and Molecular Aspects, pp. 187-200. New York: Raven Press, 1996.
19. Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., Chan, S. Y., Roczniak, S., and Shanafelt, A. B. The functional role of the ELR motif in CXC chemokine mediated angiogenesis. J. Biol. Chem., 270: 27348-27357, 1995.
20. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D., and Strieter, R. M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest., 12: 2792-2802, 1996.
21. Tosato, G., Sgadari, C., Taga, K., Jones, K. D., Pike, S. E., Rosenberg, A., Sechler, J. M. G., Magrath, I. T., Love, L. A., and Bhatia, K. Treatment of experimental Burkitt's lymphomas with normal human B cell immortalized with EBV. Blood, 83: 776-784, 1994.
22. Luster, A. D., and Leder, P. IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med., 178: 1057-1065, 1993.
23. Laning, J., Kawasaki, H., Tanaka, E., Luo, Y., and Dorf, M. E. Inhibition of in vivo tumor growth by the beta chemokine, TCA3. J. Immunol., 153: 4625-4635, 1994.
24. Mule, J. J., Custer, M., Averbook, B., Yang, J. C., Weber, J. S., Goeddel, D. V., Rosenberg, S. A., and Schall, T. J. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther., 7: 1545-1553, 1996.
25. Rollins, B. J., and Sunday, M. E. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell. Biol., 11: 3125-3131, 1991.
26. Wang, J. M., Taraboretti, G., Matsushima, K., Van Damme, J., and Mantovani, A. IL-8 induces haptotaxis and chemotaxis of melanoma cells. Biochem. Biophys. Res. Commun., 169: 165-169, 1990.
27. Benke, R., and Schirrmacher, V. Changes in organotropism of mouse lymphoma variants associated with selective cbemotactic responsiveness to organ-derived chemoattractants. Clin. Exp. Metastasis, 9: 205-219, 1991.
28. Wakabayashi, H., Cavanaugh, P. G., and Nicolson, A. L. Purification and identification of mouse lung microvessel endothelial cell-derived chemoattractant for lung-metastasizing murine RAW117 large-cell lymphoma cells: identification as mouse monocyte chemotactic protein 1. Cancer Res., 55: 4458-4464, 1995.
29. Janik, J. E., Gause, B. L., and Oppenheim, J. J. Principles of cytokine biotherapy. In: J. J. Oppenheim, J. L. Rossio, and A. J. H. Gearing (eds.), Clinical Applications of Cytokines, pp. 129-135. New York: Oxford University Press Inc., 1993.
30. Fenton, R. G., and Longo, D. L. Genetic instability and tumor cell variation: implications for immunotherapy. J. Natl. Cancer. Inst., 87: 241-243, 1995.
31. Markowitz, S., Wang, J. Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattain, M., and Willson, J. K. V. Inactivation of the type II TGF-receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
32. Wang, J., Sun, L., Myeroff, L., Wang, X., Gentry, L. E., Yang, J., Liang, J., Zborowska, E., Markowitz, S., Willson, J. K. V., and Brattain, G. Demonstration that mutation of the type II TGF-receptor inactivates its tumor suppressor activity in RER positive colon carcinoma cells. J. Biol. Chem., 270: 22044-22049, 1995.
33. Piali, I., Michel, A., Terpe, H. J., Imbol, B. A., and Gisler, R. H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med., 181: 811-816, 1995.
34. Onrusa, S. V., Hartl, M., Rosen, S. D., and Hanahan, D. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest., 97: 54-64, 1996.
35. Leach, D. R., Krummel, M. F., and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Washington DC), 271: 1734-1736, 1996.
36. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C., and Tschopp, J. Melanoma cell expression of FAS/ (APO1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.